Don't let it get away!
Keep track of the stocks that matter to you.
Help yourself with the Fool's FREE and easy new watchlist service today.
(Don't worry, I'm done rhyming.)
The ticker will be gone -- oh, WYE, WYE, WYE? Not even a hyphenated name will remain. What would founders John and Frank Wyeth think?
Of course, it hadn't been Wyeth for very long -- only since 2002. Before that it was American Home Products. A catchy name, for sure. But not the company Wyeth had become.
Turning into a Johnson & Johnson (NYSE: JNJ ) , Abbott Labs (NYSE: ABT ) , or Bayer wasn't in the cards. It shunned its agriculture division, household products and candy -- yes, candy! -- years earlier. Wyeth had become a pharmaceutical specialist. Perhaps that was its downfall?
Or maybe it was Fen-phen. Merck's (NYSE: MRK ) Vioxx was its only saving grace -- from having Fen-phen mentioned every time safety issues arose.
Whatever the reason, Pfizer liked what it saw: a nice vaccine in Prevnar and a biologic with Enbrel. Those should be much harder to copy than Lipitor, that's for sure.
Ironically, it was a smaller acquisition of American Cyanamid that jump-started vaccines. Enbrel came through an Immunex partnership, before Amgen (Nasdaq: AMGN ) snatched it up. Wonder what Pfizer could have gotten. Several smaller purchases instead of the $68 billion one?
No matter, it's done.
On to cost-saving-synergy lists that can't fail.
It's the pipeline I'm worried about;
R&D doesn't scale.
(Sorry, couldn't help myself.)
What are your expectations of the new Pfizer? Would you buy shares today (or tomorrow)? Let us know in the comments below.